Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 1 1

Status

Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2Thoracic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Ovarian Neoplasms 2Prostatic Neoplasms 1Pancreatic Neoplasms 1Lung Neoplasms 1Liver Neoplasms 1Esophageal Neoplasms 1Colonic Neoplasms 1Breast Neoplasms 1

Interventions

Paclitaxel 69Bevacizumab 62Carboplatin 53pembrolizumab 46olaparib 32Specimen Handling 27Gemcitabine 27Cyclophosphamide 26Magnetic Resonance Spectroscopy 24liposomal doxorubicin 22Cisplatin 21niraparib 20Taxes 18Nivolumab 18fludarabine 17Topotecan 17Biopsy 17Doxorubicin 14Immunoglobulin G 12Fulvestrant 12Disulfides 12Oxaliplatin 10mirvetuximab soravtansine 9durvalumab 9aldesleukin 9Surveys and Questionnaires 9Ipilimumab 9Fluorouracil 9Blood Specimen Collection 9cemiplimab 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Ovarian Neoplasms × NP-G2-044 × 1 year × Clear all
NCT07109414 2026-03-09

Trial of NP-G2-044 (Prilukae) Combined With PLD for Treatment of Platinum-Resistant Ovarian Cancer (ULTIMUS-1)

Novita Pharmaceuticals, Inc.

Phase 2/3 Active not recruiting
380 enrolled
Gynecologic

Ovarian Neoplasms

NCT03199586 2025-07-20

Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Treatment-Refractory Solid Tumor Malignancies

Novita Pharmaceuticals, Inc.

Phase 1 Completed
23 enrolled
BreastGastrointestinalGenitourinaryGynecologicThoracic

Breast Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Liver Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡